PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, USA.\', \'Adimab LLC, Lebanon, New Hampshire, USA.\', \'U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA.\', \'The Geneva Foundation, Tacoma, Washington, USA.\', \'Department of Chemistry and Life Science, United States Military Academy at West Point, West Point, New York, USA.\', \'Department of Biochemistry, Albert Einstein College of Medicine, New York, New York, USA.\', \'Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, New York, New York, USA.\', \'Department of Molecular Biosciences, The University of Texas at Austingrid.89336.37, Austin, Texas, USA.\', \'Department of Science, Mount St. Mary\'s University, Emmitsburg, Maryland, USA.\', \'Department of Radiology and Radiological Services, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.\', \'Adagio Therapeutics Inc., Waltham, Massachusetts, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1128/mBio.02473-21
?:doi
?:hasPublicationType
?:journal
  • mBio
is ?:pmid of
?:pmid
?:pmid
  • 34607456
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 4.106
?:rankingScore_hIndex
  • 71
?:title
  • A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all